FDA Calendar

PDUFA dates and FDA Panel Review dates are very important catalysts because they are ‘make or break events’ for biotech stocks.

The goal date set by the FDA for announcing its decision on a company’s New Drug Application/ Biologics License Application/sBLA/sNDA after reviewing the applications is known as the PDUFA date.

Usually, the stocks experience a run-up going into the scheduled FDA Approval decision/FDA Panel review events. So, having prior knowledge of the key dates goes a long way toward maximizing profit or minimizing loss while investing in the volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes Biotech and Pharma sectors. Check out RTT Biotech Investor and our Biotech Home Page.
Company Name
AMP-100 (NDA)
FDA decision on AMP-100 for ocular surface anesthesia and intraoperative pain management during ocular surgery.
FDA decision on BRUKINSA in the expanded use of treating adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma
On Jun.13,2022, the FDA notified the company that the decision date has been extended to Jan.20, 2023-
GSK plc
Daprodustat (NDA)
FDA panel to review Daprodustat for the potential treatment of anaemia due to chronic kidney disease (CKD) in adult patients on dialysis and not on dialysis.
Y-mAbs Therapeutics, Inc.
OMBLASTYS (Resubmitted BLA)
FDA panel to review OMBLASTYS for Neuroblastoma
Amicus Therapeutics Inc.
Cipaglucosidase alfa, a component of AT-GAA (BLA)
FDA decision on Cipaglucosidase alfa, a component of AT-GAA, for Pompe disease
Ipsen SA
Palovarotene (Resubmitted NDA)
FDA panel to review Palovarotene for the prevention of heterotopic ossification in adults and children with fibrodysplasia ossificans progressiva
AstraZeneca PLC
PT027. (NDA)
FDA panel to review PT027 in proposed indication of as-needed treatment or prevention of bronchoconstriction and for the prevention of exacerbations in patients with asthma 4 years of age and older
Ardelyx, Inc
FDA panel to review XPHOZAH for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.
Travere Therapeutics Inc
FDA decision on Sparsentan for the treatment of IgA nephropathy
Provention Bio, Inc.
Teplizumab (Resubmitted BLA)
FDA decision on Teplizumab for the delay of type 1 diabetes (T1D).

ALSO READ - COVID-19 Drugs In Development Calendar which lists Companies that are in Race to find a Treatment or Vaccine for the Novel Coronavirus.

Buy this Content

Ionis Pharmaceuticals, Inc. (IONS) said topline results from the phase 2bSOLANO study in patients with hypercholesterolemia showed that 60mg of ION449 administered monthly achieved a statistically significant 62.3% reduction in low-density lipoprotein cholesterol levels after 28 weeks compared to placebo,...
AstraZeneca PLC (AZN.L, AZN) announced Ultomiris has been approved in Europe as an add-on to standard therapy for the treatment of adult patients with generalised myasthenia gravis who are anti-acetylcholine receptor antibody-positive. The approval follows the positive opinion of the Committee for Medicinal...
Veracyte, Inc. (VCYT) said new data show that the company's Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease. The data from the VANDAAM Phase 2 study suggest that the genomic test...
Read More
A latest study done by researchers at the Medical College of Georgia and the Georgia Cancer Center at Augusta University has revealed that a large number of people who have overcome cancer are living in poverty and this is taking a drastic toll on their physical and mental health. With the help...
Shares of Synairgen plc (SNG.L) were gaining more than 5 percent in the morning trading in London after the respiratory company developing SNG001 reported positive findings from the analysis of data from 60 and 90-day follow-up visits from the Phase 3 SPRINTER trial in patients hospitalised with COVID-19. SNG001...
Known coronavirus positive cases in the United States have fallen significantly in the last two weeks, by 29 percent, according to the New York Times' latest data. A 6 percent decrease was recorded in Covid casualties in the country during the same period.
Read More